Short answer: finasteride takes months, not weeks. Its label says daily use for at least three months is generally needed before benefit. Compare progress over six to twelve months, but report new symptoms earlier. Shedding alone does not prove the drug is working.
Because treatment continues over months, compare the longer-term budget as well as the first order. Our finasteride cost comparison shows six- and twelve-month totals, pharmacy refills and the amount paid upfront.
Finasteride blocks type II 5-alpha reductase and reduces DHT, which contributes to male pattern hair loss. The roughly 65% to 70% reduction often quoted is a blood measurement, not an equivalent scalp measurement. Hair changes lag behind hormone changes, so judging a cosmetic result after only a few weeks is unreliable.
Visible improvement is not expected immediately. Use the first month to establish the prescribed daily routine and take clear baseline photographs. Side effects still need attention even when it is too early to judge hair growth.
Some people report shedding after starting or changing hair treatment, but a dependable finasteride-specific percentage or a mandatory shedding phase has not been established. Shedding is not proof of response. Tell the clinician about abrupt, heavy, patchy or persistent shedding, especially with scalp pain, redness or other symptoms.
Some men notice less progression or early thickening; others do not yet see a change. Compare photos taken with the same lighting, angle, hair length and styling. Stabilization can count as benefit, but ongoing rapid loss deserves review.
This is a useful interval for a clinician to review response, adherence and tolerability. The label's blinded photograph outcomes show that not everyone gains visible hair, even with consistent treatment. Improvement in the crown or mid-scalp does not establish reliable regrowth at the temples.
Some men continue to improve after the first year. The finasteride label reports benefit in its five-year follow-up, but individual results and the available follow-up population matter. There is no guaranteed date when maximum regrowth occurs.
Maintenance. If treatment is helping, the aim is to maintain benefit; further regrowth varies. Discontinuation at any point means the DHT suppression ends and most of the regained hair sheds within 6–12 months.
Blinded photograph assessments in the finasteride trials found increased growth in 48% of treated men versus 7% with placebo at one year, and 66% versus 7% at two years. Those are photograph outcomes, not the same thing as hair counts or patient satisfaction. Maintaining hair can be worthwhile even if a photograph does not show regrowth.
Predictors of better response:
Advanced loss and long-standing bald areas may respond less well. The label does not establish efficacy for bitemporal recession. Scarring or a different cause of shedding needs evaluation; a hair-loss pattern cannot be diagnosed from response to a tablet alone.
Do not use the first three symptom-free months as a guarantee of future tolerance. In first-year trials, the combined rate of decreased libido, erectile dysfunction or ejaculation disorder was 3.8% with finasteride versus 2.1% with placebo. Later labeling includes persistent sexual symptoms, depression and suicidal thoughts or behavior, without a reliably known frequency.
Report sexual or breast symptoms promptly. Stop finasteride 1 mg and seek medical advice for depression or suicidal thoughts, with emergency help if you cannot stay safe. Throat swelling or trouble breathing is an emergency. Read the full side-effect guide; cosmetic progress should not delay care.
Review the diagnosis, photographs, actual use, new medicines and possible shedding triggers before declaring treatment failure. A clinician can discuss whether another option is appropriate, rather than automatically increasing the dose:
No topical finasteride product is FDA-approved in the United States. Compounded formulations can be absorbed into the bloodstream and transferred to others, including pregnant people. The FDA's 2025 alert warns against assuming topical use removes systemic risks. It is not a proven faster or risk-free substitute after oral side effects.
You see yourself in the mirror every day — which makes gradual change nearly invisible. Take standardized baseline photos (front, top, crown — same lighting, same distance, same hair state). Repeat monthly. At month 6 and month 12, compare back to baseline. Comparable photos help assess change, but the clinician should interpret them alongside symptoms and the history.
If you're looking to start finasteride, a Bidwell hair loss telehealth visit covers:
Medication cost is paid separately at the pharmacy and varies by medication, quantity, pharmacy, insurance, and discount-card pricing. The $45 online visit is separate from medication cost.
There is no guaranteed way to make finasteride work faster. Take only the prescribed dose and review progress with consistent photographs. A clinician may discuss another treatment, but adding medication also adds risks.
The FDA-approved hair-loss dose is 1 mg once daily. The 5 mg product is for BPH, not a routine hair-loss escalation. Do not increase or split a different-strength tablet without the prescriber's directions.
Increased shedding after starting treatment is not automatically normal or proof of benefit. Contact the clinician if it is sudden, heavy, persistent or patchy, or accompanied by scalp pain, redness, scarring or other symptoms. Do not wait six or twelve months for concerning changes.
Bidwell's hair-loss service is for adult men. Finasteride is contraindicated in pregnancy, and people who are or could be pregnant must not handle broken or crushed tablets. Women with hair loss need an appropriate evaluation; testing and treatment depend on the history and examination.
Some men maintain benefit with long-term use, but continued treatment needs periodic assessment of benefits and risks. Finasteride can lower PSA; tell the clinician interpreting a test about its use. New mood, sexual, breast or allergic symptoms should be addressed at any time, not only at an annual review.
These sources support the medication facts and research discussed above. Study results apply to the doses and populations tested; they do not guarantee an individual outcome.